{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+dose+formulation",
    "query": {
      "intervention": "Low dose formulation"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 117,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+dose+formulation&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T06:04:40.577Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03249740",
      "title": "A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neovascular Age-Related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "GB-102",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Graybug Vision",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2017-08-29",
      "completion_date": "2019-01-16",
      "has_results": false,
      "last_update_posted_date": "2019-12-20",
      "last_synced_at": "2026-09-05T06:04:40.577Z",
      "location_count": 8,
      "location_summary": "Gilbert, Arizona • Beverly Hills, California • Indianapolis, Indiana + 5 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Lynbrook",
          "state": "New York"
        },
        {
          "city": "Abilene",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03249740"
    },
    {
      "nct_id": "NCT01444846",
      "title": "Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Temporary Auditory Threshold Shift"
      ],
      "interventions": [
        {
          "name": "SPI-1005 Low dose",
          "type": "DRUG"
        },
        {
          "name": "SPI-1005 Middle dose",
          "type": "DRUG"
        },
        {
          "name": "SPI-1005 High dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sound Pharmaceuticals, Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "31 Years",
        "sex": "ALL",
        "summary": "18 Years to 31 Years"
      },
      "enrollment_count": 83,
      "start_date": "2011-09",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-09-05T06:04:40.577Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01444846"
    },
    {
      "nct_id": "NCT02189343",
      "title": "Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "ACY-1215 in combination with pomalidomide and dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2014-09-15",
      "completion_date": "2018-04-30",
      "has_results": false,
      "last_update_posted_date": "2019-11-21",
      "last_synced_at": "2026-09-05T06:04:40.577Z",
      "location_count": 3,
      "location_summary": "Dallas, Texas • San Antonio, Texas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02189343"
    },
    {
      "nct_id": "NCT01091649",
      "title": "Study in Healthy Adults to Evaluate the Bioavailability of Two Test Tablet Formulations of ABT-450",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "ABT-450",
          "type": "DRUG"
        },
        {
          "name": "ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2010-02",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2010-12-21",
      "last_synced_at": "2026-09-05T06:04:40.577Z",
      "location_count": 1,
      "location_summary": "Waukegan, Illinois",
      "locations": [
        {
          "city": "Waukegan",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01091649"
    },
    {
      "nct_id": "NCT04062669",
      "title": "A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Virus Diseases"
      ],
      "interventions": [
        {
          "name": "Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline Placebo",
          "type": "DRUG"
        },
        {
          "name": "RabAvert",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 160,
      "start_date": "2019-08-13",
      "completion_date": "2022-07-01",
      "has_results": false,
      "last_update_posted_date": "2024-03-01",
      "last_synced_at": "2026-09-05T06:04:40.577Z",
      "location_count": 4,
      "location_summary": "South Miami, Florida • Lenexa, Kansas • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04062669"
    },
    {
      "nct_id": "NCT01486017",
      "title": "A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bioavailability of ASP015K",
        "Pharmacokinetics of ASP015K",
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "ASP015K",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2011-09",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2011-12-06",
      "last_synced_at": "2026-09-05T06:04:40.577Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01486017"
    },
    {
      "nct_id": "NCT04798027",
      "title": "Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "SARS-CoV-2 mRNA vaccine formulation 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 mRNA vaccine formulation 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SARS-CoV-2 mRNA vaccine formulation 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (0.9% normal saline)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 182,
      "start_date": "2021-03-12",
      "completion_date": "2022-06-27",
      "has_results": true,
      "last_update_posted_date": "2025-09-11",
      "last_synced_at": "2026-09-05T06:04:40.577Z",
      "location_count": 12,
      "location_summary": "Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more",
      "locations": [
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04798027"
    },
    {
      "nct_id": "NCT05090358",
      "title": "Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Cancer Stage IV",
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Ketogenic Diet",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Low Carbohydrate Diet",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Alpelisib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2021-10-08",
      "completion_date": "2027-10-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-05T06:04:40.577Z",
      "location_count": 9,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "East White Plains",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05090358"
    },
    {
      "nct_id": "NCT01896505",
      "title": "A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "KCP-330",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Karyopharm Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2013-07-30",
      "completion_date": "2016-10-21",
      "has_results": true,
      "last_update_posted_date": "2024-01-08",
      "last_synced_at": "2026-09-05T06:04:40.577Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01896505"
    },
    {
      "nct_id": "NCT05257343",
      "title": "Efficacy of a Low Dose, Oral, Liquid Iron Supplement on Restoring Inadequate Blood Iron to Normal Levels",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Iron Deficiency (Without Anemia)"
      ],
      "interventions": [
        {
          "name": "Liquid Placebo Supplementation",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Liquid Iron Supplement (Blood Builder ®)",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Applied Science & Performance Institute",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 95,
      "start_date": "2022-02-07",
      "completion_date": "2022-12-09",
      "has_results": false,
      "last_update_posted_date": "2023-05-30",
      "last_synced_at": "2026-09-05T06:04:40.577Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05257343"
    }
  ]
}